Author Correction: Blinatumomab in pediatric patients with relapsed/refractory acute lymphoblastic leukemia: results of the RIALTO trial, an expanded access study (Blood Cancer Journal, (2020), 10, 7, (77), 10.1038/s41408-020-00342-x)

Franco Locatelli; G. Zugmaier; N. Mergen; P. Bader; S. Jeha; Schlegel P. -G.; Bourquin J. -P.; R. Handgretinger; B. Brethon; C. Rossig; C. Chen-Santel

doi:10.1038/s41408-021-00413-7

Author Correction: Blinatumomab in pediatric patients with relapsed/refractory acute lymphoblastic leukemia: results of the RIALTO trial, an expanded access study (Blood Cancer Journal, (2020), 10, 7, (77), 10.1038/s41408-020-00342-x)

Franco Locatelli, G. Zugmaier^*, N. Mergen, P. Bader, S. Jeha, Schlegel P. -G., Bourquin J. -P., R. Handgretinger, B. Brethon, C. Rossig, C. Chen-Santel

^*Autore corrispondente per questo lavoro

Risultato della ricerca: Contributo in rivista › Articolo

Abstract

The original version of the article contained an error in Fig. 1b, which showed that 57/69 (78.3%) of patients with CR in the first 2 cycles achieved MRD response. The article has now been corrected to state 57/69 (82.6%). (Figure presented.).

Lingua originale	Inglese
pagine (da-a)	1-1
Numero di pagine	1
Rivista	Blood Cancer Journal
Volume	11
Numero di pubblicazione	2
DOI	https://doi.org/10.1038/s41408-021-00413-7
Stato di pubblicazione	Pubblicato - 2021

All Science Journal Classification (ASJC) codes

Ematologia
Oncologia

Keywords

blinatumomab

OSS delle Nazioni Unite

Questo processo contribuisce al raggiungimento dei seguenti obiettivi di sviluppo sostenibile

Accesso al documento

10.1038/s41408-021-00413-7

Altri file e collegamenti

Fingerprint

Entra nei temi di ricerca di 'Author Correction: Blinatumomab in pediatric patients with relapsed/refractory acute lymphoblastic leukemia: results of the RIALTO trial, an expanded access study (Blood Cancer Journal, (2020), 10, 7, (77), 10.1038/s41408-020-00342-x)'. Insieme formano una fingerprint unica.

Cita questo

Locatelli, F., Zugmaier, G., Mergen, N., Bader, P., Jeha, S., -G., S. P., -P., B. J., Handgretinger, R., Brethon, B., Rossig, C., & Chen-Santel, C. (2021). Author Correction: Blinatumomab in pediatric patients with relapsed/refractory acute lymphoblastic leukemia: results of the RIALTO trial, an expanded access study (Blood Cancer Journal, (2020), 10, 7, (77), 10.1038/s41408-020-00342-x). Blood Cancer Journal, 11(2), 1-1. https://doi.org/10.1038/s41408-021-00413-7

@article{1f56bf9b2b01481eb1c36b4a99d79720,

title = "Author Correction: Blinatumomab in pediatric patients with relapsed/refractory acute lymphoblastic leukemia: results of the RIALTO trial, an expanded access study (Blood Cancer Journal, (2020), 10, 7, (77), 10.1038/s41408-020-00342-x)",

abstract = "The original version of the article contained an error in Fig. 1b, which showed that 57/69 (78.3%) of patients with CR in the first 2 cycles achieved MRD response. The article has now been corrected to state 57/69 (82.6%). (Figure presented.).",

keywords = "blinatumomab, blinatumomab",

author = "Franco Locatelli and G. Zugmaier and N. Mergen and P. Bader and S. Jeha and -G., {Schlegel P.} and -P., {Bourquin J.} and R. Handgretinger and B. Brethon and C. Rossig and C. Chen-Santel",

year = "2021",

doi = "10.1038/s41408-021-00413-7",

language = "English",

volume = "11",

pages = "1--1",

journal = "Blood Cancer Journal",

issn = "2044-5385",

publisher = "Nature Publishing Group",

number = "2",

}

Locatelli, F, Zugmaier, G, Mergen, N, Bader, P, Jeha, S, -G., SP, -P., BJ, Handgretinger, R, Brethon, B, Rossig, C & Chen-Santel, C 2021, 'Author Correction: Blinatumomab in pediatric patients with relapsed/refractory acute lymphoblastic leukemia: results of the RIALTO trial, an expanded access study (Blood Cancer Journal, (2020), 10, 7, (77), 10.1038/s41408-020-00342-x)', Blood Cancer Journal, vol. 11, n. 2, pagg. 1-1. https://doi.org/10.1038/s41408-021-00413-7

Author Correction: Blinatumomab in pediatric patients with relapsed/refractory acute lymphoblastic leukemia: results of the RIALTO trial, an expanded access study (Blood Cancer Journal, (2020), 10, 7, (77), 10.1038/s41408-020-00342-x). / Locatelli, Franco; Zugmaier, G.; Mergen, N. et al.
In: Blood Cancer Journal, Vol. 11, N. 2, 2021, pag. 1-1.

Risultato della ricerca: Contributo in rivista › Articolo

TY - JOUR

T1 - Author Correction: Blinatumomab in pediatric patients with relapsed/refractory acute lymphoblastic leukemia: results of the RIALTO trial, an expanded access study (Blood Cancer Journal, (2020), 10, 7, (77), 10.1038/s41408-020-00342-x)

AU - Locatelli, Franco

AU - Zugmaier, G.

AU - Mergen, N.

AU - Bader, P.

AU - Jeha, S.

AU - -G., Schlegel P.

AU - -P., Bourquin J.

AU - Handgretinger, R.

AU - Brethon, B.

AU - Rossig, C.

AU - Chen-Santel, C.

PY - 2021

Y1 - 2021

N2 - The original version of the article contained an error in Fig. 1b, which showed that 57/69 (78.3%) of patients with CR in the first 2 cycles achieved MRD response. The article has now been corrected to state 57/69 (82.6%). (Figure presented.).

AB - The original version of the article contained an error in Fig. 1b, which showed that 57/69 (78.3%) of patients with CR in the first 2 cycles achieved MRD response. The article has now been corrected to state 57/69 (82.6%). (Figure presented.).

KW - blinatumomab

UR - https://publicatt.unicatt.it/handle/10807/229211

UR - https://www.scopus.com/inward/citedby.uri?partnerID=HzOxMe3b&scp=85101117755&origin=inward

UR - https://www.scopus.com/inward/record.uri?partnerID=HzOxMe3b&scp=85101117755&origin=inward

U2 - 10.1038/s41408-021-00413-7

DO - 10.1038/s41408-021-00413-7

M3 - Article

SN - 2044-5385

VL - 11

SP - 1

EP - 1

JO - Blood Cancer Journal

JF - Blood Cancer Journal

IS - 2

ER -

Locatelli F, Zugmaier G, Mergen N, Bader P, Jeha S, -G. SP et al. Author Correction: Blinatumomab in pediatric patients with relapsed/refractory acute lymphoblastic leukemia: results of the RIALTO trial, an expanded access study (Blood Cancer Journal, (2020), 10, 7, (77), 10.1038/s41408-020-00342-x). Blood Cancer Journal. 2021;11(2):1-1. doi: 10.1038/s41408-021-00413-7